
1. Technology overview
Cortechs.ai is a neuroimaging software company with headquarters in San Diego, California, and says it has been quantifying for more than 18 years. It develops AI that turns routine MRI, PET and CT scans into standardized volumetric measurements.
The NeuroQuant suite covers brain segmentation and volumetrics, NeuroQuant MS lesion tracking, NeuroQuant Brain Tumor, Lesion Surveillance for ARIA, NeuroQuant PET and NeuroQuant CT, plus OnQ Prostate for prostate MRI. The company reports more than 1,500 institutions and availability in 44 countries, with scanner-vendor partners including Siemens Healthineers, Philips, GE HealthCare and Canon Medical.
2. Highlighted features & specifications
- NeuroQuant: brain segmentation and volumetrics with longitudinal tracking.
- NeuroQuant MS: lesion visualization and volume change for multiple sclerosis.
- Lesion Surveillance: FLAIR, T2*GRE and SWI lesion monitoring, including ARIA.
- NeuroQuant PET: tracer quantification, FDA-cleared in August 2026.
- NeuroQuant Brain Tumor: pre- and post-operative volume analysis.
- OnQ Prostate: prostate MRI analysis with restriction spectrum imaging mapping.
3. Potential application
Neurology departments in Vietnam could track brain atrophy and MS lesions between MRI follow-ups. Imaging centers could add prostate MRI quantification to their reports. Hospitals joining an AI platform such as CARPL.ai could deploy NeuroQuant alongside other tools.
4. Benefits
Turns routine scans into standardized volumes that support objective reads.
Expanded EU MDR CE marking for NeuroQuant version 5 allows sale across the European Economic Area.
Available through scanner-vendor and AI-marketplace channels, reducing integration effort.
SOC 2 compliant, with a public trust center.
5. Market trends & opportunities
Anti-amyloid therapies and MS care raise demand for quantitative MRI monitoring. Imaging AI is increasingly distributed through scanner vendors and enterprise AI platforms. Southeast Asian hospitals buying 3T MRI systems can access such tools through vendor channels.
6. Other information
Headquarters at 5060 Shoreham Place, San Diego, California. Expanded EU MDR CE marking for NeuroQuant version 5 reported in August 2026; NeuroQuant PET received FDA 510(k) clearance in August 2026. Customers listed include MD Anderson, Johns Hopkins Medicine and Cedars-Sinai.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































